{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:31:53Z","timestamp":1791959513713,"version":"4.3.4"},"reference-count":47,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T00:00:00Z","timestamp":1499040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Cerus Corporation","award":["\u2022\u2022\u2022"],"award-info":[{"award-number":["\u2022\u2022\u2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Concerned over the risk of Zika virus (ZIKV) transfusion transmission, public health agencies recommended the implementation of mitigation strategies for its prevention. Those strategies included the use of pathogen inactivation for the treatment of plasma and platelets. The efficacy of amotosalen\/ultraviolet A to inactivate ZIKV in plasma had been previously demonstrated, and the efficacy of inactivation in platelets with the same technology was assumed. These studies quantify ZIKV inactivation in platelet components using amotosalen\/ultraviolet A.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>Platelet components were spiked with ZIKV, and ZIKV infectious titers and RNA loads were measured by cell culture\u2010based assays and real\u2010time polymerase chain reaction in spiked platelet components before and after photochemical treatment using amotosalen\/ultraviolet A.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The mean ZIKV infectivity titers and RNA loads in platelet components before inactivation were either 4.9 log<jats:sub>10<\/jats:sub> plaque forming units per milliliter, or 4.4 log<jats:sub>10<\/jats:sub> 50% tissue culture infective dose per milliliter and 7.5 log<jats:sub>10<\/jats:sub> genome equivalents per milliliter, respectively. No infectivity was detected immediately after amotosalen\/ultraviolet A treatment. No replicative virus remained after treatment, as demonstrated by multiple passages on Vero cell cultures; and ZIKV RNA was not detected from the first passage after inactivation. Additional experiments in this study demonstrated efficient inactivation to the limit of detection in platelets manufactured in 65% platelet additive solution, 35% plasma, or 100% plasma.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>As previously demonstrated for plasma, robust levels of ZIKV inactivation were achieved in platelet components. With inactivation of higher levels of ZIKV than those reported in asymptomatic, RNA\u2010reactive blood donors, the pathogen\u2010inactivation system using amotosalen\/ultraviolet A offers the potential to mitigate the risk of ZIKV transmission by plasma and platelet transfusion.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.14161","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T11:42:54Z","timestamp":1499082174000},"page":"2016-2025","source":"Crossref","is-referenced-by-count":26,"title":["Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination"],"prefix":"10.1111","volume":"57","author":[{"given":"Felicia","family":"Santa Maria","sequence":"first","affiliation":[{"name":"Cerus Corporation Concord California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Laughhunn","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion C.","family":"Lanteri","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Aubry","sequence":"additional","affiliation":[{"name":"P\u00f4le de Recherche et de Veille sur les Maladies Infectieuses \u00c9mergentes, Institut Louis Malard\u00e9  Tahiti Polyn\u00e9sie Fran\u00e7aise."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Musso","sequence":"additional","affiliation":[{"name":"P\u00f4le de Recherche et de Veille sur les Maladies Infectieuses \u00c9mergentes, Institut Louis Malard\u00e9  Tahiti Polyn\u00e9sie Fran\u00e7aise."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adonis","family":"Stassinopoulos","sequence":"additional","affiliation":[{"name":"Cerus Corporation Concord California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,3]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"World Health Organization. Zika virus microcephaly and Guillain\u2010Barre syndrome situation report [cited 2017 May 18]. Geneva Switzerland: World Health Organization;2017. Available from:http:\/\/apps.who.int\/iris\/bitstream\/10665\/254507\/1\/zikasitrep2Feb17-eng.pdf?ua=1:1-0000."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00072-15"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv322"},{"key":"e_1_2_7_5_1","unstructured":"ChuangV WongTY LeungYH et al. Review of dengue fever cases in Hong Kong during 1998 to 2005; Hong Kong Med J.2008;14:170\u20107."},{"key":"e_1_2_7_6_1","article-title":"Transfusion transmitted dengue: one donor infects two patients","author":"Karim F","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13054"},{"key":"e_1_2_7_8_1","first-page":"2944","article-title":"Imported cases of chikungunya in metropolitan France, April 2005 to February 2006","volume":"11","author":"Cordel H","year":"2006","journal-title":"Euro Surveill"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13681"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1607262"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2015.03.001"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14018"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2304.161549"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/voxs.12335"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2014.19.14.20761"},{"key":"e_1_2_7_16_1","unstructured":"US Department of Health and Human Services. Recommendations for donor screening deferral and product management to reduce the risk of transfusion transmission of Zika virus. Guidance for industry. Silver Spring (MD): US Food and Drug Administration Center for Biologics Evaluation and Research; 2016 [cited 2017 May 18]. Available from:https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/guidancecomplianceregulatoryinformation\/guidances\/blood\/ucm518213.pdf."},{"key":"e_1_2_7_17_1","unstructured":"US Department of Health and Human Services. Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components. Guidance for industry. Silver Spring (MD): US Food and Drug Administration Center for Biologics Evaluation and Research;2016[cited 2017 May 18]. Available from:http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Blood\/UCM518213.pdf."},{"key":"e_1_2_7_18_1","unstructured":"World Health Organization. Maintaining a safe and adequate blood supply during Zika virus outbreaks [cited 2017 May 18]. Available from:http:\/\/apps.who.int\/iris\/bitstream\/10665\/204436\/1\/WHO_ZIKV_HS_16.1_eng.pdf?ua=1WHO\/ZIKV\/HS\/16.1."},{"key":"e_1_2_7_19_1","unstructured":"AABB. Updated recommendations for Zika dengue and chikungunya viruses. AABB Association Bulletin 16\u201007 [cited 2017 May 18]. Available from:https:\/\/www.aabb.org\/programs\/publications\/bulletins\/Documents\/."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14029"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2004.11.005"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000323937"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00867.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00844.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.12-0603"},{"key":"e_1_2_7_26_1","first-page":"225A","article-title":"High titers of dengue virus in platelet concentrates are inactivated by treatment with amotosalen and UVA light","volume":"52","author":"Dupuis K","year":"2012","journal-title":"Transfusion"},{"key":"e_1_2_7_27_1","first-page":"189","article-title":"Amotosalen and ultraviolet A illumination inactivation of Zika virus in plasma","volume":"109","author":"Aubry MTP","year":"2015","journal-title":"Vox Sang"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12713"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13271"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/genomeA.00917-16"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138161"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13993"},{"key":"e_1_2_7_33_1","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed LJ","year":"1938","journal-title":"Am J Trop Med Hyg"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14028"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14031"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14041"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13519"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.4236\/aid.2013.31001"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13729"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00584.x"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.1.292.bloodjournal821292"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13360"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-737981"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00867.x"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0041-1132.2005.04316.x"},{"key":"e_1_2_7_46_1","unstructured":"US Food and Drug Administration (FDA). INTERCEPT Blood System for Platelets\u2010SPC 00334\u2010AW V3.0\u2010DRAFT 7 [cited 2017 May 18]. Silver Spring (MD): FDA;2016. Available from:https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/PremarketApprovalsPMAs\/UCM427512.pdf."},{"key":"e_1_2_7_47_1","first-page":"7","article-title":"Inactivation of chikungunya virus with amustaline\/GSH in red blood cells","volume":"111","author":"Laughhunn A","year":"2016","journal-title":"Vox Sang"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.01522"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14161","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T01:06:32Z","timestamp":1695517592000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,3]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/trf.14161"],"URL":"https:\/\/doi.org\/10.1111\/trf.14161","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,3]]}}}